Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1) > Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1):68-76

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

REVIEW  FREEfree


Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1):68-76

DOI: 10.23736/S0392-0488.17.05795-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Pathways in melanoma development

Tal H. ERLICH 1, David E. FISHER 1, 2

1 Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA; 2 Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA


PDF  


This review aimed to summarize the current advances in melanoma research and their clinical relevance. Until recently, melanoma was considered an incurable disease. However, in recent years tremendous advances have been made in therapeutics. This is due to profound understanding of the molecular pathways involved in melanoma development. Although new targets are always emerging, understanding how to overcome resistance to current treatments is of great interest.


KEY WORDS: Melanoma - Molecular targeted therapy - Immunotherapy

top of page

Publication History

Issue published online: January 8, 2018
Manuscript accepted: October 5, 2017
Manuscript received: October 1, 2017

Cite this article as

Erlich TH, Fisher DE. Pathways in melanoma development. G Ital Dermatol Venereol 2018;153:68-76. DOI: 10.23736/S0392-0488.17.05795-9

Corresponding author e-mail

dfisher3@mgh.harvard.edu